1.1 The TCTCN Credential: Rename, Scope & Official Test Blueprint
Key Takeaways
- ONCC renamed the Blood and Marrow Transplant Certified Nurse (BMTCN®) credential to the Transplantation and Cellular Therapy Certified Nurse (TCTCN™) credential effective January 1, 2026; the program was renamed rather than retired, and existing certificants were transitioned automatically with new certificates issued in the first quarter of 2026.
- The TCTCN™ test consists of 165 multiple-choice questions with four options each, of which 125 are scored and 40 are unscored pretest items; the three-hour session includes roughly 15 minutes for the computer tutorial and post-test survey, leaving about one minute per question.
- The Test Content Outline, based on a 2024 role delineation study, has six major subject areas: Foundations of HSCT and Cellular Therapy (22%), HSCT and Cellular Therapy Process and Administration (22%), Post-HSCT Management and Education (22%), Post-Cellular Therapy Management and Education (22%), Quality of Life (8%), and Professional Performance (4%); item counts are derived by multiplying each percentage by the 125 scored items.
- Four of the six subject areas carry identical 22% weights, so no single domain dominates the test; Quality of Life (8%, about 10 scored items) and Professional Performance (4%, about 5 scored items) together account for only 12% of the scored total.
- Every major subject area appears on every form of the test with its assigned percentage, but ONCC states that not all content sub-areas are included on every form.
About the TCTCN Exam: Scope, Blueprint & Certification Logistics
The Evolution of the Credential: From BMTCN® to TCTCN™
Effective January 1, 2026, the Oncology Nursing Certification Corporation (ONCC) renamed the Blood and Marrow Transplant Certified Nurse (BMTCN®) credential to the Transplantation and Cellular Therapy Certified Nurse (TCTCN™) credential. ONCC is explicit that the program was renamed, not retired: the certification, the sponsoring body, and the eligibility pathway all continue, and nurses who held BMTCN® at the transition were moved to the TCTCN™ credential automatically, with new certificates issued in the first quarter of 2026 and new digital badges during 2026. After January 2026, BMTCN® should no longer be used as a post-nominal.
The renaming accompanied a scheduled blueprint update. ONCC describes the TCTCN™ Test Content Outline as, in many ways, the four-year refresh the BMTCN® outline would have received anyway - with more cellular therapy content because the nursing role itself evolved. The current outline is built on a role delineation study completed in 2024.
For decades, hematopoietic cell transplantation (HCT) was synonymous with bone marrow, peripheral blood stem cell, and umbilical cord blood grafts. However, the rapid clinical maturation and regulatory approval of immune effector cell (IEC) therapies—including autologous Chimeric Antigen Receptor (CAR) T-cell therapies, Tumor-Infiltrating Lymphocytes (TILs), engineered T-cell Receptor (TCR) therapies, natural killer (NK) cell platforms, and ex vivo CRISPR/Cas9 gene-edited hematopoietic stem cell therapies (e.g., for sickle cell disease and transfusion-dependent beta-thalassemia)—fundamentally expanded specialized nursing practice.
ONCC explains that the name change reflects the evolution of treatment and nursing practice. The 2026 outline, based on the 2024 role delineation study, now makes HSCT and cellular-therapy knowledge explicit without creating a different level or jurisdiction of certification.
┌─────────────────────────────────────────────────────────────────────────┐
│ THE TCTCN ECOSYSTEM & ROLES │
├──────────────────────────┬──────────────────────────────────────────────┤
│ ONCC │ Legally responsible credentialing body; │
│ │ establishes eligibility, test outlines, │
│ │ pass standards, and ILNA renewal criteria. │
├──────────────────────────┼──────────────────────────────────────────────┤
│ ASTCT / EBMT / FACT │ Professional societies & accreditation bodies│
│ │ establishing clinical guidelines, cellular │
│ │ therapy grading (ASTCT consensus), & quality.│
├──────────────────────────┼──────────────────────────────────────────────┤
│ ONS / APHON │ Professional nursing associations publishing │
│ │ clinical curriculum, textbooks, and CE. │
├──────────────────────────┼──────────────────────────────────────────────┤
│ PSI Services (PSI) │ Third-party psychometric testing vendor │
│ │ administering computer-based tests at PSI sites. │
└──────────────────────────┴──────────────────────────────────────────────┘
Scope Comparison: BMTCN® vs. TCTCN™
The table below highlights the key evolutionary differences between the legacy BMTCN® framework and the current TCTCN™ examination framework:
| Practice Dimension | Legacy BMTCN® Framework | Current TCTCN™ Framework (2026+) | Clinical & Exam Impact |
|---|---|---|---|
| Primary Therapeutic Modalities | Autologous & allogeneic bone marrow, PBSC, and cord blood transplantation. | Autologous & allogeneic HSCT plus CAR-T, TILs, TCRs, NK cells, and gene-edited therapies. | Nurses must master viral vector biology, lymphodepleting chemotherapy, and genetic editing platforms. |
| Complication Focus | Graft-versus-Host Disease (GVHD), graft failure, engraftment syndrome, SOS/VOD. | Classical HSCT complications plus Cytokine Release Syndrome (CRS), ICANS, HLH/MAS, and IEC-HS. | Dedicated 22% domain testing acute immune-mediated toxicities and rapid intervention pathways. |
| Cell Processing & Chain of Custody | Cryopreservation, DMSO toxicity, ABO incompatibility, marrow harvest. | DMSO/cryo plus apheresis collection for viral transduction, vein-to-vein tracking, and FACT IEC standards. | Strict emphasis on chain of identity (COI), chain of custody (COC), and cellular release criteria. |
| Target Patient Population | Hematologic malignancies, aplastic anemia, select primary immunodeficiencies. | Hematologic malignancies, non-malignant hemoglobinopathies, solid tumors (TILs), and autoimmune diseases. | Broader pathophysiology spanning oncology, hematology, and emerging non-malignant cellular gene therapies. |
| Credential Blueprint Balance | Post-transplant complications were assessed largely as a single body of HSCT content. | Two distinct, equally weighted subject areas: Post-HSCT Management and Education (22%) and Post-Cellular Therapy Management and Education (22%). | Equal preparation required for HSCT immunology and adoptive cellular immunotherapy pathways. |
The Six Official Subject Areas
The TCTCN™ Test Content Outline is composed of six major subject areas, each carrying a published percentage. The test consists of 165 multiple-choice questions; 125 count toward your score and 40 are unscored pretest (experimental) items that you cannot identify while testing. ONCC states the conversion rule precisely: multiply the subject-area percentage by 125, the scored total - not by 165. Every major subject area appears on every form with its assigned percentage, but ONCC notes that not all content sub-areas appear on every form.
| # | Official Subject Area | Weight | Scored Items (of 125) | High-Yield Clinical Core Topics |
|---|---|---|---|---|
| I | Foundations of HSCT and Cellular Therapy | 22% | ~28 | Hematopoietic cell lineage and function, immune system function, histocompatibility/HLA typing, goals of therapy, indications, types of HSCT and cellular therapy (autologous, allogeneic, CAR-T, TIL, NK cells, bispecific antibodies, gene therapy, DLI), sources of cells, recipient suitability and evaluation, and recipient/caregiver/donor education. |
| II | HSCT and Cellular Therapy Process and Administration | 22% | ~28 | Cellular therapy product collection and storage; HSCT product mobilization, collection, harvest and storage; conditioning/preparative regimens (intensity, chemotherapy, radiation/TBI, biotherapy, immunotherapy, targeted therapy); management of acute complications of preparative regimens; and product administration (fresh vs. cryopreserved, infusion and injection management, hematologic compatibilities). |
| III | Post-HSCT Management and Education | 22% | ~28 | Early: immunosuppressive therapy, aGVHD, infection prevention and management, sepsis, hematologic and immune complications, acute system-specific complications, graft rejection/failure, chimerism, symptom management. Late: cGVHD and photopheresis, system-specific late effects, immunizations and prophylaxis, disease relapse, subsequent malignancy, follow-up care and milestone visits. |
| IV | Post-Cellular Therapy Management and Education | 22% | ~28 | Early: infection prevention and management, sepsis, hematologic support, immune toxicities (neurotoxicity, CRS, HLH-like syndrome), symptom management, treatment failure. Late: system-specific late effects (neurotoxicity, pancytopenia, hypogammaglobulinemia), immunizations and prophylaxis, disease relapse, subsequent malignancy, follow-up care and milestone visits. |
| V | Quality of Life | 8% | 10 | Navigation and coordination throughout the continuum, psychosocial and caregiver support, health promotion and maintenance, sexuality, cultural and spiritual competence, survivorship, palliative care, and end-of-life care. |
| VI | Professional Performance | 4% | 5 | Nursing scope of practice; evidence-based practice, research and quality improvement; communication and interprofessional collaboration; professional development; environmental health and safety; ethical and legal considerations; accreditation (FACT, The Joint Commission, REMS); and self-care. |
| All six subject areas | 100% | 125 scored + 40 pretest = 165 items | 3-hour test session |
Structural insight worth memorizing: four subject areas are weighted identically at 22%. There is no single "biggest domain" among I–IV to prioritize. The only genuinely small areas are Quality of Life (8%, ~10 scored items) and Professional Performance (4%, ~5 scored items) - together just 12% of your score, which is exactly why candidates should not spend a third of their study time there. Note also that the outline splits post-procedure care into two parallel 22% areas, one for HSCT and one for cellular therapy, each containing its own early and late phases. Learning them as a matched pair - and noticing where they differ - is the single most efficient way to cover 44% of the scored items.
Which statement accurately describes the test blueprint weighting and item distribution of the TCTCN examination?